Lung-restricted antibodies lead to lung allograft rejection

Lung allografts have the worst survival of all solid organs with >50% graft loss at 5 years. Primary graft dysfunction (PGD), characterized by pulmonary edema and hypoxemic respiratory failure, occurs within the first 24 to 72 hours of lung transplantation in over 50% of lung recipients and remains the predominant cause of early post-transplant mortality as well as chronic rejection. As such, amelioration of PGD has the potential to dramatically improve both the short- and long-term outcomes following lung transplantation.